206 related articles for article (PubMed ID: 29454314)
21. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
[TBL] [Abstract][Full Text] [Related]
22. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study.
Casjens S; Weber DG; Johnen G; Raiko I; Taeger D; Meinig C; Moebus S; Jöckel KH; Brüning T; Pesch B
BMJ Open; 2017 Oct; 7(10):e017104. PubMed ID: 29025836
[TBL] [Abstract][Full Text] [Related]
23. Clinical Response of Live-Attenuated,
Hassan R; Alley E; Kindler H; Antonia S; Jahan T; Honarmand S; Nair N; Whiting CC; Enstrom A; Lemmens E; Tsujikawa T; Kumar S; Choe G; Thomas A; McDougall K; Murphy AL; Jaffee E; Coussens LM; Brockstedt DG
Clin Cancer Res; 2019 Oct; 25(19):5787-5798. PubMed ID: 31263030
[TBL] [Abstract][Full Text] [Related]
24. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
[TBL] [Abstract][Full Text] [Related]
26. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
[TBL] [Abstract][Full Text] [Related]
27. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.
Weber DG; Casjens S; Johnen G; Bryk O; Raiko I; Pesch B; Kollmeier J; Bauer TT; Brüning T
PLoS One; 2014; 9(12):e114483. PubMed ID: 25469901
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
29. Use of Serum Mesothelin as an Indicator of Tumor Progression in Routine Clinical Practice of Malignant Pleural Mesothelioma Treatment.
Vigani A; Pistillo MP; Fontana V; Giannoni U; Rosenberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
J Thorac Oncol; 2018 Aug; 13(8):e143-e145. PubMed ID: 30049376
[No Abstract] [Full Text] [Related]
30. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
[TBL] [Abstract][Full Text] [Related]
31. The Correlation of Serum Mesothelin Level With Pleural Thickness in Malignant Pleural Mesothelioma Makes it a Valuable Tool for Monitoring Tumor Progression.
Fontana V; Vigani A; Pistillo MP; Giannoni U; Rosemberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
J Thorac Oncol; 2019 May; 14(5):e92-e94. PubMed ID: 31027749
[No Abstract] [Full Text] [Related]
32. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
33. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
34. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
[TBL] [Abstract][Full Text] [Related]
35. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.
Klikovits T; Stockhammer P; Laszlo V; Dong Y; Hoda MA; Ghanim B; Opitz I; Frauenfelder T; Nguyen-Kim TDL; Weder W; Berger W; Grusch M; Aigner C; Klepetko W; Dome B; Renyi-Vamos F; Oehler R; Hegedus B
Sci Rep; 2017 Nov; 7(1):16456. PubMed ID: 29184132
[TBL] [Abstract][Full Text] [Related]
36. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
38. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
Santarelli L; Staffolani S; Strafella E; Nocchi L; Manzella N; Grossi P; Bracci M; Pignotti E; Alleva R; Borghi B; Pompili C; Sabbatini A; Rubini C; Zuccatosta L; Bichisecchi E; Valentino M; Horwood K; Comar M; Bovenzi M; Dong LF; Neuzil J; Amati M; Tomasetti M
Lung Cancer; 2015 Dec; 90(3):457-64. PubMed ID: 26431916
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
Verma V; Wegner RE; Brooks ED; Miccio JA; Kann BH; Finley GG; Raj MS; Grover S; Mohindra P; Simone CB
Clin Lung Cancer; 2019 Jul; 20(4):263-269. PubMed ID: 30992187
[TBL] [Abstract][Full Text] [Related]
40. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
Felten MK; Khatab K; Knoll L; Schettgen T; Müller-Berndorff H; Kraus T
Int Arch Occup Environ Health; 2014 Feb; 87(2):195-204. PubMed ID: 23423281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]